Tailoring immunotherapy with liquid biopsy Sorry about the #paywall https://t.co/MV8U6rX2UJ
An @NatureCancer editorial on the INSPIRE trial (☝️) by the amazing @JeanneTie of @PeterMacCC @WEHI https://t.co/ifFI82GWzA
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully i…
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully i…
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully i…
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully i…
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully i…
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully i…
T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
RT @Dr_Ivanoncologo: Tailoring #immunotherapy with #LiquidBiopsy by Jeanne Tie https://t.co/CUMPZNDjKh @pashtoonkasi @aparna1024 @FilipJan…
RT @Dr_Ivanoncologo: Tailoring #immunotherapy with #LiquidBiopsy by Jeanne Tie https://t.co/CUMPZNDjKh @pashtoonkasi @aparna1024 @FilipJan…
the kinetics of circulating tumor DNA reflect response and resistance to immunotherapy treatment across multiple cancer types and could be used to tailor treatment. #liquidbiopsy https://t.co/l92lKqaJX5
@AdrianDubuc @OICR_news @pmcancercentre @CG_Consortium Here's a link to the paper, out in @NatureCancer a couple of months ago: https://t.co/fvKx12N6cY ...and succintly reviewed here: https://t.co/CshOADCMAL
RT @VivekSubbiah: Tailoring immunotherapy with liquid biopsy @NatureCancer https://t.co/itafJ8jUUB
Tailoring immunotherapy with liquid biopsy @NatureCancer https://t.co/itafJ8jUUB
Great review article published in #JCOPO looking at the clinical utility of ctDNA monitoring with Signatera to predict immunotherapy treatment #SignateraLooksDeeper https://t.co/YHAkJwRO6i
Great review article published in #JCOPO highlighting the clinical utility of ctDNA monitoring w/ Signatera to predict immunotherapy treatment #SignateraLooksDeeper https://t.co/z2wjRjj9oH
RT @NateraOncology: 🆕 In this review article published in #JCOPO, Jeanne Tie, MD explores the clinical utility of ctDNA monitoring with Sig…
RT @NateraOncology: 🆕 In this review article published in #JCOPO, Jeanne Tie, MD explores the clinical utility of ctDNA monitoring with Sig…
🆕 In this review article published in #JCOPO, Jeanne Tie, MD explores the clinical utility of ctDNA monitoring with Signatera to predict immunotherapy treatment. View the abstract below! https://t.co/PvYaPnMx0o
RT @Dr_Ivanoncologo: Tailoring #immunotherapy with #LiquidBiopsy by Jeanne Tie https://t.co/CUMPZNDjKh @pashtoonkasi @aparna1024 @FilipJan…
RT @Dr_Ivanoncologo: Tailoring #immunotherapy with #LiquidBiopsy by Jeanne Tie https://t.co/CUMPZNDjKh @pashtoonkasi @aparna1024 @FilipJan…
RT @Dr_Ivanoncologo: Tailoring #immunotherapy with #LiquidBiopsy by Jeanne Tie https://t.co/CUMPZNDjKh @pashtoonkasi @aparna1024 @FilipJan…
RT @Kristel_GT: Rising ctDNA level from baseline to the beginning of Cycle 3 [6-7 weeks] after beginning treatment,predicts lack of respons…
Rising ctDNA level from baseline to the beginning of Cycle 3 [6-7 weeks] after beginning treatment,predicts lack of response to pembrolizumab(PPV 97.5%). Patient with Imaging progression + Rising ctDNA levels early=Very likely True Progression & Unlike
RT @Dr_Ivanoncologo: Tailoring #immunotherapy with #LiquidBiopsy by Jeanne Tie https://t.co/CUMPZNDjKh @pashtoonkasi @aparna1024 @FilipJan…